1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells

Immunology Letters

Volumn 134, Issue 1, 2010, Pages 7-16

  Ikeda, Utako ^a   Wakita, Daiko ^a   Ohkuri, Takayuki ^a   Chamoto, Kenji ^a   Kitamura, Hidemitsu ^a   Iwakura, Yoichiro ^b   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Th17; Vitamin A; Vitamin D

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BETA ACTIN; CALCITRIOL; CD45RB ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR RELATED ORPHAN RECEPTOR C; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CONCENTRATION RESPONSE; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DOWN REGULATION; DRUG POTENTIATION; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DERMATITIS, CONTACT; DRUG SYNERGISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKINS; KERATOLYTIC AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TH17 CELLS; TRETINOIN; VITAMIN D; VITAMINS;

EID: 78049265765     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.07.002     Document Type: Article

References (67)

1. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
2. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999, 190:617-627.
3. Chamoto K., Tsuji T., Funamoto H., Kosaka A., Matsuzaki J., Sato T., et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004, 64:386-390.
4. Wakita D., Chamoto K., Ohkuri T., Narita Y., Ashino S., Sumida K., et al. IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 2009, 30:1408-1415.
5. Ohkuri T., Wakita D., Chamoto K., Togashi Y., Kitamura H., Nishimura T. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br J Cancer 2009, 100:1135-1143.
6. Nishimura T., Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. J Immunol 1999, 162:6503-6509.
7. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
8. Parkin J., Cohen B. An overview of the immune system. Lancet 2001, 357:1777-1789.
9. Hoshino A., Tsuji T., Matsuzaki J., Jinushi T., Ashino S., Teramura T., et al. STAT6-mediated signaling in Th2-dependent allergic asthma: critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation. Int Immunol 2004, 16:1497-1505.
10. Ashino S., Wakita D., Zhang Y., Chamoto K., Kitamura H., Nishimura T. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung. Int Immunol 2008, 20:259-266.
11. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662-687.
12. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001, 167:4974-4980.
13. Imazeki I., Matsuzaki J., Tsuji K., Nishimura T. Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity. Biomed Res 2006, 27:1-9.
14. Matsuzaki J., Tsuji T., Zhang Y., Wakita D., Imazeki I., Sakai T., et al. 1alpha,25-Dihydroxyvitamin D3 downmodulates the functional differentiation of Th1 cytokine-conditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lymphocyte generation. Cancer Sci 2006, 97:139-147.
15. Lemire J.M., Archer D.C. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991, 87:1103-1107.
16. Tsuji M., Fujii K., Nakano T., Nishii Y. 1 Alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett 1994, 337:248-250.
17. Mathieu C., Waer M., Laureys J., Rutgeerts O., Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994, 37:552-558.
18. Lemire J.M., Ince A., Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992, 12:143-148.
19. Gregori S., Giarratana N., Smiroldo S., Uskokovic M., Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1367-1374.
20. Gorman S., Kuritzky L.A., Judge M.A., Dixon K.M., McGlade J.P., Mason R.S., et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 2007, 179:6273-6283.
21. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002, 195:603-616.
22. Alroy I., Towers T.L., Freedman L.P. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995, 15:5789-5799.
23. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
24. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
25. Tajima M., Wakita D., Noguchi D., Chamoto K., Yue Z., Fugo K., et al. IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med 2008, 205:1019-1027.
26. Ashino S., Wakita D., Shiohama Y., Iwakura Y., Chamoto K., Ohkuri T., et al. A T(h)17-polarized cell population that has infiltrated the lung requires cells that convert to IFN-{gamma} production in order to induce airway hyperresponsiveness. Int Immunol 2010, 22:503-513.
27. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508.
28. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
29. Aarvak T., Chabaud M., Miossec P., Natvig J.B. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162:1246-1251.
30. Teunissen M.B., Koomen C.W., de Waal Malefyt R., Wierenga E.A., Bos J.D. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998, 111:645-649.
31. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
32. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008, 324:23-33.
33. Tang J., Zhou R., Luger D., Zhu W., Silver P.B., Grajewski R.S., et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 2009, 182:4624-4632.
34. Borgogni E., Sarchielli E., Sottili M., Santarlasci V., Cosmi L., Gelmini S., et al. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Endocrinology 2008, 149:3626-3634.
35. Colin E.M., Asmawidjaja P.S., van Hamburg J.P., Mus A.M., van Driel M., Hazes J.M., et al. 1,25-Dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010, 62:132-142.
36. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
37. Elias K.M., Laurence A., Davidson T.S., Stephens G., Kanno Y., Shevach E.M., et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008, 111:1013-1020.
38. Berenbaum M.C. What is synergy?. Pharmacol Rev 1989, 41:93-141.
39. Selleseth D.W., Talarico C.L., Miller T., Lutz M.W., Biron K.K., Harvey R.J. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob Agents Chemother 2003, 47:1468-1471.
40. Chen A.I., McAdam A.J., Buhlmann J.E., Scott S., Lupher M.L., Greenfield E.A., et al. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999, 11:689-698.
41. Nakae S., Komiyama Y., Nambu A., Sudo K., Iwase M., Homma I., et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17:375-387.
42. He D., Wu L., Kim H.K., Li H., Elmets C.A., Xu H. CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol 2006, 177:6852-6858.
43. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
44. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
45. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007, 8:639-646.
46. Liu H., Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008, 180:7948-7957.
47. Hill J.A., Hall J.A., Sun C.M., Cai Q., Ghyselinck N., Chambon P., et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi cells. Immunity 2008, 29:758-770.
48. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
49. Yang L., Anderson D.E., Baecher-Allan C., Hastings W.D., Bettelli E., Oukka M., et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352.
50. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649.
51. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
52. Zhou L., Lopes J.E., Chong M.M., Ivanov I.I., Min R., Victora G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
53. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
54. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453:106-109.
55. Kimura A., Naka T., Nohara K., Fujii-Kuriyama Y., Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A 2008, 105:9721-9726.
56. Chung Y., Yang X., Chang S.H., Ma L., Tian Q., Dong C. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 2006, 16:902-907.
57. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
58. Ortega C., Fernandez A.S., Carrillo J.M., Romero P., Molina I.J., Moreno J.C., et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009.
59. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
60. Kryczek I., Bruce A.T., Gudjonsson J.E., Johnston A., Aphale A., Vatan L., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008, 181:4733-4741.
61. Burton J.M., O'Connor P.W., Hohol M., Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009, CD006921.
62. Klarenbeek N.B., Allaart C.F., Kerstens P.J., Huizinga T.W., Dijkmans B.A. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009, 21:291-298.
63. Lips P. Hypervitaminosis A and fractures. N Engl J Med 2003, 348:347-349.
64. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008, 14:275-281.
65. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008, 14:282-289.
66. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
67. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118:597-607.